SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma in jubilant mood on reporting stellar Q4 numbers

27 Apr 2012 Evaluate

Ajanta Pharma is currently trading at Rs. 564.60, up by 25.30 points or 4.69% from its previous closing of Rs. 539.30 on the BSE.

The scrip opened at Rs. 550.00 and has touched a high and low of Rs. 566.85 and Rs. 548.00 respectively. So far 46750 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 571.00 on 25-Apr-2012 and a 52 week low of Rs. 242.50 on 28-Apr-2011.

Last one week high and low of the scrip stood at Rs. 571.00 and Rs. 532.00 respectively. The current market cap of the company is Rs. 656.85 crore.

The promoters holding in the company stood at 70.13% while Institutions and Non-Institutions held 0.60% and 29.27% respectively.

Ajanta Pharma has reported results for fourth quarter ended March 31, 2012.

On the standalone basis, the company has posted a rise of 35.11% in its net profit at Rs 23.59 crore for the quarter ended March 31, 2012 as compared to Rs 17.46 crore for the same quarter in the previous year. Total income has increased by 39.83% at Rs 176.10 crore for quarter under review as compared to Rs 125.94 crore for the quarter ended March 31, 2011.

For the full year ended March 31, 2012, on the consolidated basis, the company has posted a rise of 52.36% in its net profit at Rs 77.26 crore for the year ended March 31, 2012 as compared to Rs 50.71 crore for the same period in the previous year. Total income has increased by 35.80% at Rs 677.39 crore for year under review as compared to Rs 498.82 crore for the period ended March 31, 2011.

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×